Clinical Research
The Conrad Pearson Clinic is a leader in clinical research and is unique in that we are the only practice in the region that has such a wide breadth of clinical research offerings. Led by Dr. Paul Eber and Dr. Michael Granieri, our research team offers clinical trials to allow us to remain at the forefront of medicine and to allow our patient access to the newest treatment options.
All advances in modern medicine are made through the process of clinical research. A clinical trial is a study that is carefully designed to answer specific questions about the safety and effectiveness of new medications, treatments, therapies or surgical techniques. We participate in trials of all these types.
Why Should I Participate in a Study?
Clinical trials offer real benefits to current and future patients. A study will often offer access to a new treatment option that is not currently available to the public. These new options are usually designed to address a specific short-coming in current medical practice, and thus they often appeal to patients. You will receive very detailed and specific care from the research team before and during the trial. In addition to potentially receiving the investigational treatment, you have the added benefit of contributing to the future of medicine.
Are Trials Safe?
All medical treatments and choices, including clinical trials, involve risks. There are, however, layers of oversight to help keep patients safe. Clinical trial protocols are nearly always approved by the FDA and by an IRB (institutional review board) before being offered to patients. These are independent entities that help ensure patient safety. Patients on a trial are cared for by CRCs (clinical research coordinators) who are experts at trial conduct and patient care and will work closely with each patient. Investigators on the trial are physicians or providers whose ultimate responsibility is to ensure patient safety and provide attentive care for any issues that arise.
The entire team at Conrad Pearson believes that access to these trials benefit our patients and we strive to offer the best treatments available.
Current Clinical Trials at Conrad Pearson Clinic
Bladder Cancer — Advanced 2 – Protara
Evaluating the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer
Inclusion Criteria: Participants aged 18 years or older with a confirmed diagnosis of high-grade non-muscle invasive bladder cancer.
Interested in participating and want to learn more about enrollment criteria?
Email: RSGrigsby@conradpearson.com
Phone: 901-236-0957
Bladder Cancer — Interpath
Study of V940 in Combination with BCG Versus BCG Monotherapy and or V940 by itself in Participants with High-risk
Inclusion Criteria: Participants aged 18 years or older with a confirmed diagnosis of high-risk non-muscle invasive bladder cancer.
Interested in participating and want to learn more about enrollment criteria?
Email: RSGrigsby@conradpearson.com
Phone: 901-236-0957
Bladder Cancer — Moonrise 3
Comparing TAR-210 to intravesc chemo in patients with bladder cancer
Inclusion Criteria: Participants aged 18 years or older with a confirmed diagnosis of papillary non-muscle invasive bladder cancer.
Interested in participating and want to learn more about enrollment criteria?
Email: RSGrigsby@conradpearson.com
Phone: 901-236-0957
Benign Prostate Hyperplasia (BPH) — ALPFA (Coming Soon – March 2026)
Transurethral focused Ultrasound for the ablation of prostate tissue
Inclusion Criteria: Male participants with benign prostatic hyperplasia (BPH).
More details coming soon.
Benign Prostatic Hyperplasia (BPH) — iTind – Olympus
Study to compare the Nitinol (iTind) device vs. UroLift device for patients with Benign Prostatic Hyperplasia
Inclusion Criteria: Male participants aged 50 years or older with benign prostatic hyperplasia (BPH).
Interested in participating and want to learn more about enrollment criteria?
Email: RSGrigsby@conradpearson.com
Phone: 901-236-0957
Benign Prostatic Hyperplasia (BPH) – RAPID III – Rivermark
Evaluating the safety and Efficacy of the FloStent device in men suffering from Benign Prostatic Hyperplasia
Inclusion Criteria: Male participants aged 45 years or older with benign prostatic hyperplasia (BPH).
Interested in participating and want to learn more about enrollment criteria?
Email: RSGrigsby@conradpearson.com
Phone: 901-236-0957
Stress Incontinence in Prostate Cancer — ARID II
Device study for the Treatment of Post Prostatectomy Stress Urinary Incontinence in Males
Inclusion Criteria: Male participants aged 45 years or older who have been diagnosed with prostate cancer and scheduled for robotic assisted radical prostatectomy.
Interested in participating and want to learn more about enrollment criteria?
Email: RSGrigsby@conradpearson.com
Phone: 901-236-0957
Prostate Cancer — Telix Bi-Pass (Coming Soon – Nov 2025)
(Diagnostic Trial) – Evaluating whether combining PET/imaging and MRI improves the detection of Prostate Cancer compared to Standard of Care.
Inclusion Criteria: Male participants aged 18 years or older with clinical suspicion of prostate cancer and no prior prostate biopsy.
More details coming soon.
Prostate Cancer — Telix – ProstAct (Coming Soon – Nov 2025)
Evaluating the effectiveness of experimental drug (Lutetium + Standard of Care) vs. (Standard of Care Alone)
Inclusion Criteria: Participants who have previous treatment with APRI’s and have documented metastatic progression.
More details coming soon.
